PHILADELPHIA - Globally, the influenza virus, or flu, is thought to cause between three and five million cases of severe illness and between 250,000 and 500,000 deaths annually, according to the World Health Organization. New strains of the virus emerge each year, so that the U.S. Centers for Disease Control and other public health services must produce and distribute a new vaccine against the new flu strains each year. And each year, people seeking to avoid a flu infection must arrange to receive a flu shot - rarely a pleasant experience - from their doctor or other health-care provider. Also, the effectiveness of the vaccine is known to decline in the elderly, a population for whom flu infections can be particularly dangerous.
A new prototype vaccine developed by researchers at The Wistar Institute, however, might be able to protect recipients not only against this year's strains of the virus, but also against those yet to come, possibly eliminating the need for an annual shot. In fact, because the vaccine would be administered as a nasal spray, it could eliminate the need for a shot of any kind. A report on the new findings appears in the June 2 issue of the journal Vaccine.
"Current vaccines are quite effective, but they are based on regions of the virus that mutate rapidly, so health officials are constantly faced with the problem of updating the vaccines," says Walter Gerhard, M.D., senior author on the Vaccine report and a professor in the immunology program at The Wistar Institute. "A vaccine directed against a more stable region of the virus would offer important public-health advantages, and this is what we are hoping to be able to develop."
Current flu vaccines trigger an immune response to a pair of prominent viral-coat proteins that mutate constantly, which is the reason last year's flu vaccine is ineffective against this year's flu strains. The experimental vaccine contains an engineered peptide that mimics a third, smaller viraPage: 1 2 3 Related biology news :1
Contact: Franklin Hoke
The Wistar Institute
. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting2
. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients3
. Novel approaches to current cellular therapies continue progress toward disease prevention4
. Novel therapies show promise against myeloid leukemia5
. Novel sensors help clear the air6
. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs7
. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis8
. Novel therapeutic target identified in fight against Rheumatoid Arthritis9
. Novel bacterium detoxifies chlorinated pollutants10
. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician11
. Novel method identifies hidden genes